Clinical-stage pharmaceutical company EntreMed Inc (ENMD) Tuesday announced that Dr Ken K Ren has been appointed as the Interim Chief Executive Officer of the company with effect from April 2, 2012.
Dr Ren has earned for himself a renowned name in the pharmaceutical industry, having been associated with drug discovery, development and regulatory issues. He brings with him years of experience in in conducting global trials for multi-national pharmaceutical and biotech companies, EntreMed added.
Commenting on his appointment, Executive Chairman Dr. Wei-Wu He said: "We are very excited to bring Dr. Ren on board to be a part of our team. Dr. Ren has a tremendous amount of experience with conducting international trials, including in the U.S. and China. This experience and expertise, along with his practical business sense and personal record of starting and building successful companies, will make Ken instrumental to achieving EntreMed's business objectives.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.